Compile Data Set for Download or QSAR
Report error Found 165 Enz. Inhib. hit(s) with all data for entry = 7816
TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220356(US9290488, A11a(i))
Affinity DataEC50:  139nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220357(US9290488, A11a(ii))
Affinity DataEC50:  42.5nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220358(US9290488, B2a(i))
Affinity DataEC50:  319nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220359(US9290488, B2a(ii))
Affinity DataEC50:  61.3nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220360(US9290488, B11a(i))
Affinity DataEC50:  16.2nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220361(US9290488, B11a(ii))
Affinity DataEC50:  6.54nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220362(US9290488, B12a)
Affinity DataEC50:  8.14nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220363(US9290488, B20a(i))
Affinity DataEC50:  2.62nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataEC50:  51.1nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220365(US9290488, B21a)
Affinity DataEC50:  7.80nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220366(US9290488, B34a)
Affinity DataEC50:  1.24nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220368(US9290488, C20a(ii))
Affinity DataEC50:  146nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220371(US9290488, E53a(i))
Affinity DataEC50:  65.7nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220372(US9290488, E53a(ii))
Affinity DataEC50:  130nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220373(US9290488, E54a)
Affinity DataEC50:  21.7nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220374(US9290488, H3a)
Affinity DataEC50:  40.1nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220375(US9290488, K2b(ii))
Affinity DataEC50:  14.3nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220376(US9290488, K29b)
Affinity DataEC50:  7.24nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220377(US9290488, L2b(i))
Affinity DataEC50:  14.6nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220378(US9290488, L2b(ii))
Affinity DataEC50:  12nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220379(US9290488, L29b)
Affinity DataEC50:  4.20nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220380(US9290488, ZA01)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220381(US9290488, ZA02)
Affinity DataEC50:  24.2nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220382(US9290488, ZA03)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220383(US9290488, ZA04)
Affinity DataEC50:  5.84nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220384(US9290488, ZA05)
Affinity DataEC50:  24.5nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220385(US9290488, ZA06)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220386(US9290488, ZA07)
Affinity DataEC50:  22.9nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220387(US9290488, ZA08)
Affinity DataEC50:  29.3nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220388(US9290488, ZA09)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220389(US9290488, ZA10)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetOpioid growth factor receptor-like protein 1(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220390(US9290488, ZA11)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220356(US9290488, A11a(i))
Affinity DataEC50:  357nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220357(US9290488, A11a(ii))
Affinity DataEC50:  116nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220359(US9290488, B2a(ii))
Affinity DataEC50:  247nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220361(US9290488, B11a(ii))
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220362(US9290488, B12a)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220363(US9290488, B20a(i))
Affinity DataEC50:  54nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220364(US9290488, B20a(ii))
Affinity DataEC50:  363nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220365(US9290488, B21a)
Affinity DataEC50:  64nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220366(US9290488, B34a)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220372(US9290488, E53a(ii))
Affinity DataEC50:  568nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220373(US9290488, E54a)
Affinity DataEC50:  560nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220375(US9290488, K2b(ii))
Affinity DataEC50:  340nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220376(US9290488, K29b)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220377(US9290488, L2b(i))
Affinity DataEC50:  469nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220378(US9290488, L2b(ii))
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220383(US9290488, ZA04)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220384(US9290488, ZA05)
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetKappa-type opioid receptor(Human)
Purdue Pharma

US Patent
LigandPNGBDBM220356(US9290488, A11a(i))
Affinity DataEC50: >2.00E+4nMpH: 7.4 T: 2°CAssay Description:Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 165 total ) | Next | Last >>
Jump to: